Compare SWVL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWVL | CTMX |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 596.2M |
| IPO Year | N/A | 2015 |
| Metric | SWVL | CTMX |
|---|---|---|
| Price | $2.30 | $4.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.50 |
| AVG Volume (30 Days) | 7.6K | ★ 2.0M |
| Earning Date | 09-08-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | $19,329,423.00 | ★ $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $17.32 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.10 | $0.40 |
| 52 Week High | $7.20 | $4.62 |
| Indicator | SWVL | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 33.03 | 57.36 |
| Support Level | $2.20 | $3.78 |
| Resistance Level | $2.60 | $4.20 |
| Average True Range (ATR) | 0.20 | 0.24 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 22.50 | 73.88 |
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.